摘要:
The present invention is directed to a hemostatic material comprising a scaffold and a galvanic particulate. The galvanic particulate comprises particles made of at least two dissimilar metals. The scaffold is preferably a biocompatible polysaccharide-based hemostatic, such as a chitosan or cellulosic based hemostatic like ORC.
摘要:
The present invention relates to a method and device (15) for scheduling transmission of queued data packets of at least one terminal (11, 12, 13). To this end, information indicating packet queue time and queue buffer size is acquired. Further, it is determined, for each queue of the at least one terminal, whether either estimated data packet delay for any queued data packet exceeds a delay threshold value or whether number of data packets queued exceeds a buffer size, and if so, the data packets of each queue is scheduled for transmission from the at least one terminal as a respective single bundle of data.
摘要:
The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要:
Methods for allocating spectrum resources among a plurality of devices in a wireless communication network are disclosed. In one aspect, an estimated number of resource blocks required by a first device and an estimated number of resource blocks required by a second device are determined. The required number of resource blocks may be determined by considering the number of resource blocks that would be necessary to empty the buffer of a first device and/or determining the number of resource blocks that would be sufficient to cause the first device to become power limited. These estimates may then be used to calculate first and second utilization weights, which can in turn be used to calculate scheduling entity weights for a plurality of scheduling entities, such as UEs in the communication network. Allocation may be based on the scheduling entity weights, utilization weights, and/or the required number of resource blocks.
摘要:
A method (1000) for scheduling uplink transmission resources such as transmission duration and frequency to users (120) in a cell (110) of a cellular system (100). Grants for the use of uplink transmission resources are sent (1005) on a downlink control channel to users in the cell and the users' uplink transmissions are sent (1010) in subframes which have a certain extension in time and frequency. For each of at least a number of subframes, a decision (1015) is made on the number of users that will be scheduled resources for uplink transmission in the subframe, so that said number of users is maximized (1020) with respect to the control channel's capacity to transmit uplink grants for that subframe.
摘要:
A radio base station and a method therein are provided for scheduling a radio resource to a user equipment. The radio base station estimates a first channel quality and determines a pathloss between the user equipment and the serving radio base station and a gain based on the pathloss. The radio base station also obtains a gain of the user equipment towards of neighbouring radio base stations, and determines a fraction of the determined pathloss, based on the gain and the obtained gains. The radio base station further determines a second channel quality of the channel based on the estimated first channel quality, the determined fraction and the determined pathloss to be compensated for; and schedules a radio resource for the user equipment based on the determined second channel quality.
摘要:
A node of a radio access network includes a transceiver and a radio resource control unit. The transceiver is configured to facilitate communication with plural wireless terminals over a radio interface including transmissions on an uplink from the wireless terminals to the node and transmissions on a downlink from the node to the wireless terminals.The radio resource control unit configured to perform radio resource control functionality including layer three (L3) signaling between the node and the wireless terminals. The radio resource control unit includes an uplink scheduler configured to predict transmission of an uplink L3 message from the wireless terminals to the node and, for a particular wireless terminal, to generate, for transmission on the downlink, a grant message which in accordance with the prediction prioritizes a predicted L3 message of the particular wireless terminal relative to messages of others of the plural wireless terminals.
摘要:
The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要:
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要:
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.